Vertex Pharma (VRTX) Income Statement

Click line-items for a historical chart and %

Product revenues, net	409.69M
Royalty revenues	3.84M
Collaborative revenues	259K
Total revenues	413.78M
Cost of product revenues	53.22M
Royalty expenses	855K
Research and development expenses	272.37M
Sales, general and administrative expenses	106.06M
Restructuring expense	8K
Total costs and expenses	432.51M
Loss from operations	-18.73M
Interest income
Interest expense
Change in fair value of derivative instruments
Loss before provision for income taxes	-39.03M
Provision for income taxes (Alios)	503K
Net loss	-39.54M
Net loss attributable to noncontrolling interest (Alios)	696K
Net loss attributable to Vertex	-38.84M
Basic net loss attributable to Vertex per common share (in dollars per share)	-0.16
Diluted net loss attributable to Vertex per common share (in dollars per share)	-0.16
Basic weighted-average number of common shares outstanding (in shares)	244.92M
Diluted weighted-average number of common shares outstanding (in shares)	244.92M

Entities mentioned with VRTX

View All Entities